In a quarter where half of India was debating GST on samosas, Biocon quietly raised ₹4,500 crore through its first equity issue since 2004. Yes, after 21 years, they passed the hat around — and investors threw money like it was a tech IPO. Add FDA approvals, NHS tender wins, and the promise of Semaglutide in 2027, and suddenly the lab coat looks like a superhero cape. But don’t miss the plot twist: $1.15 billion debt still lurks like a bad credit card bill. Stick around — this call had more drama than a Karan Johar family reunion.
2. At a Glance
Operating revenue up 15% – Generics flunked, but biosimilars aced the test.
Biosimilars up 18% – North America turned into Netflix for Biocon.
CRDMO up 11% – Syngene proving it’s still the nerdy cousin.
Core EBITDA up 11% – Margins at 25%; CFO calls it “steady,” we call it “diet-controlled.”
PBT ex-exceptionals up 72% – Finally, some steroid-free muscle.
Net debt $1.15B – Debt diet still ongoing, interest burden heading to the treadmill.
3. Management’s Key Commentary
Quote: “QIP of ₹4,500 Cr was oversubscribed, first since 2004.” (Translation: Investors still love us, despite Viatris hangover.)
Quote: “FDA approved Kirsty, first interchangeable rapid-acting insulin in the U.S.” (Translation: We made insulin cool again. Move over Ozempic memes.)
Quote: “Yesafili won NHS tenders in the U.K.” (Translation: Free healthcare Brits said yes to Biocon instead of Pfizer’s overpriced stuff.)
Quote: “Generics hit by ₹60 Cr quarterly facility costs.” (Translation: Three shiny plants, zero short-term profits. Welcome to EMI season.)
Quote: “Biosimilars EBITDA up 36%, margins at 24%.” (Translation: This is the business paying everyone’s electricity bills.)
Quote: “IPO for Biocon Biologics? No compulsion.” (Translation: Chill, we’ll list when Netflix stops making biopics on pharma billionaires.)
